Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Burstein

Showing results (161-170 of 194) with videos related to

Pageof 20
Sort By:
The Journal of Biological Chemistry|May 15, 1992
Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substratesB Grinde, C E Cameron, J Leis, et al.
The Journal of Physiology|April 17, 2002
Modulation of human corticomotor excitability by somatosensory inputAlain Kaelin-Lang, Andreas R Luft, Lumy Sawaki, et al.
Clinical Pharmacology and Therapeutics|February 22, 2008
Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokersS L McColl, A H Burstein, K R Reeves, et al.
Journal of Clinical Pharmacology|August 22, 2006
Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokersHélène M Faessel, Bill J Smith, Megan A Gibbs, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo studyB Feng, R S Obach, A H Burstein, et al.
The Journal of Prevention of Alzheimer'S Disease|October 27, 2025
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trialsSamuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, et al.
Arthritis and Rheumatism|January 20, 1998
Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structureR B Zurier, R G Rossetti, J H Lane, et al.
European Journal of Clinical Pharmacology|July 29, 2008
Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokersH M Faessel, A H Burstein, M D Troutman, et al.
Biochemical and Biophysical Research Communications|April 15, 1991
Detection of cannabinoid receptors by photoaffinity labellingS H Burstein, C A Audette, A Charalambous, et al.
Journal of Medicinal Chemistry|August 21, 1992
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activitiesS H Burstein, C A Audette, A Breuer, et al.
Pageof 20

Showing results (161-170 of 194) with videos related to

Sort By:
Pageof 20
The Journal of Biological Chemistry|May 15, 1992
Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substratesB Grinde, C E Cameron, J Leis, et al.
The Journal of Physiology|April 17, 2002
Modulation of human corticomotor excitability by somatosensory inputAlain Kaelin-Lang, Andreas R Luft, Lumy Sawaki, et al.
Clinical Pharmacology and Therapeutics|February 22, 2008
Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokersS L McColl, A H Burstein, K R Reeves, et al.
Journal of Clinical Pharmacology|August 22, 2006
Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokersHélène M Faessel, Bill J Smith, Megan A Gibbs, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo studyB Feng, R S Obach, A H Burstein, et al.
The Journal of Prevention of Alzheimer'S Disease|October 27, 2025
The impact of recent approvals on future alzheimer's disease clinical development: Statistical considerations for combination trialsSamuel P Dickson, Craig Mallinckrodt, Aaron H Burstein, et al.
Arthritis and Rheumatism|January 20, 1998
Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structureR B Zurier, R G Rossetti, J H Lane, et al.
European Journal of Clinical Pharmacology|July 29, 2008
Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokersH M Faessel, A H Burstein, M D Troutman, et al.
Biochemical and Biophysical Research Communications|April 15, 1991
Detection of cannabinoid receptors by photoaffinity labellingS H Burstein, C A Audette, A Charalambous, et al.
Journal of Medicinal Chemistry|August 21, 1992
Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activitiesS H Burstein, C A Audette, A Breuer, et al.
Pageof 20